VivoSeq
Musculoskeletal

Arthritis, Psoriatic

5

Pipeline Programs↗

11

Active Trials↗

5

Companies Involved↗

Arthritis, Psoriatic is an early-stage landscape with 5 programs across 5 companies. The most active players are MoonLake Immunotherapeutics AG, AbbVie, Eli Lilly. 1 therapy is approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

19/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

MoonLake Immunotherapeutics AG

1 program

Phase 3AbbVie logo

AbbVie

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

ApprovedJohnson & Johnson logo

Johnson & Johnson

3 programs

ApprovedJ

Johnson & Johnson Private Limited

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

60%

Monoclonal antibody

3 of 5 classified programs — the dominant modality here.

40%ALL OTHERSSmall molecule240%

Monoclonal antibody leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 83% of 6 pipeline programs.

Analysis

Trial Status

11

clinical trials

Recruiting6 · 55%
Active, not recruiting5 · 45%

Clinical Trials

Trial Activity

11 trials

A Phase 3, Parallel-group, Randomized, Double-blind, 4-arm, Placebo-controlled, Multicenter Study With Risankizumab as Active Reference Arm, to Investigate the Efficacy and Safety of Subcutaneous Sonelokimab in Male and Female Participants Aged 18 Years and Over With Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumor Necrosis Factor-α Inhibitors
Recruiting·MMoonLake Immunotherapeutics AG·Phase 3·NCT06641089·600 enrolled
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT06807424·750 enrolled
A Real-World, Prospective Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Patients
Recruiting·Johnson & Johnson logoJohnson & Johnson·N/A·NCT07532226·200 enrolled
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-88545223 For the Treatment of Participants With Active Psoriatic Arthritis
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT07321873·240 enrolled
A Phase-IV, Multicenter, Non-Comparative, Open-Label Study Evaluating the Safety and Efficacy of Guselkumab Administered Subcutaneously in the Treatment of Indian Patients With Psoriatic Arthritis
Recruiting·JJohnson & Johnson Private Limited·Approved·NCT07141004·100 enrolled
GUselkumab for the Treatment of PsA: Effectiveness Results by Ultrasound
Recruiting·Johnson & Johnson logoJohnson & Johnson·N/A·NCT07220824·200 enrolled
A Phase 3, Parallel-group, Randomized, Double-blind, 3-arm, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Subcutaneous Sonelokimab in Male and Female Participants Aged 18 Years and Over With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs
Active, not recruiting·MMoonLake Immunotherapeutics AG·Phase 3·NCT06641076·960 enrolled
A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Who Had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor Alpha Agent
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT04936308·453 enrolled
A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Approved·NCT04929210·411 enrolled
Assessment of Guselkumab (Tremfya) and IL-17 Inhibitor Therapies in Patients With Psoriatic Arthritis in Routine Clinical Practice; A Prospective, Observational Cohort Study
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·N/A·NCT05049798·1,314 enrolled
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants With Active Psoriatic Arthritis
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT04882098·1,054 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)